Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06431620
Status:
RECRUITING
Last Update Posted:
2024-05-28
First Post:
2024-05-22
Brief Title:
Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally AdvancedMetastatic Differentiated Thyroid Cancer
Sponsor:
Nanjing First Hospital Nanjing Medical University
Organization:
Nanjing First Hospital Nanjing Medical University
Study Overview
Official Title:
Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally AdvancedMetastatic Differentiated Thyroid Cancer
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Exogenous injection of recombinant human thyroid stimulating hormone rhTSH can elevate TSH in the short term 2 days to meet the requirements of diagnostic 131I SPECTCT whole-body scans Antiangiogenic tyrosine kinase inhibitors TKI couuld alter the uptake of radioactive 131I in locally advanced or metastatic differentiated thyroid cancer rhTSH can help to perform the diagnostic 131I SPECTCT whole-body scans before and after the TKI usage rhTSH can reduce the risk of tumor progression caused by thyroid hormone withdrawal period and the side effects of hypothyroidism also caused by thyroid hormone withdrawal and clarify the 131I uptake change after TKI treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None